TY - JOUR
T1 - Opium use and risk of pancreatic cancer
T2 - A prospective cohort study
AU - Moossavi, Shirin
AU - Mohamadnejad, Mehdi
AU - Pourshams, Akram
AU - Poustchi, Hossein
AU - Islami, Farhad
AU - Sharafkhah, Maryam
AU - Mirminachi, Babak
AU - Nasseri-Moghaddam, Siavosh
AU - Semnani, Shahryar
AU - Shakeri, Ramin
AU - Etemadi, Arash
AU - Merat, Shahin
AU - Khoshnia, Masoud
AU - Dawsey, Sanford M.
AU - Pharoah, Paul D.
AU - Brennan, Paul
AU - Abnet, Christian C.
AU - Boffetta, Paolo
AU - Kamangar, Farin
AU - Malekzadeh, Reza
N1 - Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2018/3
Y1 - 2018/3
N2 - Background: We examined the association between opium consumption and pancreatic cancer incidence in a large-scale prospective cohort of the general population in northeastern Iran. Methods: A total of 50,045 adults were systematically followed up (median of 7.4 years), and incident cases of pancreatic cancer were identified. Self-reported data on opium consumption was collected at baseline. Cumulative use (-year) was defined as number of nokhods (a local unit, approximately 0.2 g) of opium consumed per day multiplied by number of years consuming. Adjusted HRs and 95% confidence intervals (CIs) for the association between opium consumption and pancreatic cancer were calculated using Cox proportional hazards regression models. Results: Overall, 54 confirmed cases of pancreatic cancer were identified. Opium use of more than 81 nokhod-years (high cumulative use), compared with never use, was strongly associated with pancreatic cancer even after adjustments for multiple potential confounding factors [HR = 3.01; 95% CI, 1.25-7.26]. High cumulative consumption of opium was significantly associated with risk of pancreatic cancer after adjusting for cumulative dose of cigarette smoking [HR = 3.56; 95% CI, 1.49-8.50]. In a sensitivity analysis, we excluded participants (including 2 pancreatic cancer cases) who were recruited within the first 5 years of starting opium consumption; high cumulative use of opium was still associated with pancreatic cancer risk [HR = 2.75; 95% CI, 1.14-6.64]. Conclusions: Our results showed a positive association between opium consumption and pancreatic cancer. Impact: This is the first prospective large-scale study to show the association of opium consumption with pancreatic cancer as a risk factor.
AB - Background: We examined the association between opium consumption and pancreatic cancer incidence in a large-scale prospective cohort of the general population in northeastern Iran. Methods: A total of 50,045 adults were systematically followed up (median of 7.4 years), and incident cases of pancreatic cancer were identified. Self-reported data on opium consumption was collected at baseline. Cumulative use (-year) was defined as number of nokhods (a local unit, approximately 0.2 g) of opium consumed per day multiplied by number of years consuming. Adjusted HRs and 95% confidence intervals (CIs) for the association between opium consumption and pancreatic cancer were calculated using Cox proportional hazards regression models. Results: Overall, 54 confirmed cases of pancreatic cancer were identified. Opium use of more than 81 nokhod-years (high cumulative use), compared with never use, was strongly associated with pancreatic cancer even after adjustments for multiple potential confounding factors [HR = 3.01; 95% CI, 1.25-7.26]. High cumulative consumption of opium was significantly associated with risk of pancreatic cancer after adjusting for cumulative dose of cigarette smoking [HR = 3.56; 95% CI, 1.49-8.50]. In a sensitivity analysis, we excluded participants (including 2 pancreatic cancer cases) who were recruited within the first 5 years of starting opium consumption; high cumulative use of opium was still associated with pancreatic cancer risk [HR = 2.75; 95% CI, 1.14-6.64]. Conclusions: Our results showed a positive association between opium consumption and pancreatic cancer. Impact: This is the first prospective large-scale study to show the association of opium consumption with pancreatic cancer as a risk factor.
UR - https://www.scopus.com/pages/publications/85045508257
U2 - 10.1158/1055-9965.EPI-17-0592
DO - 10.1158/1055-9965.EPI-17-0592
M3 - Article
C2 - 29263189
AN - SCOPUS:85045508257
SN - 1055-9965
VL - 27
SP - 268
EP - 273
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 3
ER -